BiotechTube

Ambisome + caspofungin

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Invasive Aspergillosis

Conditions

Invasive Aspergillosis

Trial Timeline

Mar 1, 2004 → May 1, 2006

NCT ID
NCT00334412

About Ambisome + caspofungin

Ambisome + caspofungin is a approved stage product being developed by Gilead Sciences for Invasive Aspergillosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00334412. Target conditions include Invasive Aspergillosis.

What happened to similar drugs?

4 of 20 similar drugs in Invasive Aspergillosis were approved

Approved (4) Terminated (2) Active (15)
🔄Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
🔄Micafungin + fluconazoleAstellas PharmaPhase 3
🔄Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
❌Micafungin + PlaceboAstellas PharmaPhase 3
✅MicafunginAstellas PharmaApproved
🔄Olorofim + AmBisome®ShionogiPhase 3
🔄Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel + Epirubicin or doxorubicin, cyclophosphamide, paclitaxelJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00334412ApprovedCompleted

Competing Products

20 competing products in Invasive Aspergillosis

See all competitors
ProductCompanyStageHype Score
BSG005Alkem LaboratoriesPhase 1/2
39
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
31
Trastuzumab deruxtecan + DurvalumabDaiichi SankyoPhase 2
42
Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
40
Micafungin + fluconazoleAstellas PharmaPhase 3
40
MicafunginAstellas PharmaPre-clinical
26
Micafungin (Mycamine)Astellas PharmaPhase 1
29
Pudexacianinium chlorideAstellas PharmaPhase 2
35
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
42
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
42
Isavuconazonium sulfate + Voriconazole + PosaconazoleAstellas PharmaPre-clinical
26
Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
44
Isavuconazonium sulfate + Isavuconazonium sulfateAstellas PharmaPhase 2
35
Micafungin + Systemic antifungal therapyAstellas PharmaPhase 2
27
MicafunginAstellas PharmaPre-clinical
26
Micafungin + PlaceboAstellas PharmaPhase 3
32
MicafunginAstellas PharmaApproved
35
Olorofim + AmBisome®ShionogiPhase 3
44
Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel + Epirubicin or doxorubicin, cyclophosphamide, paclitaxelJiangsu Hengrui MedicinePhase 3
44
SHR-A1811 + Trastuzumab EmtansineJiangsu Hengrui MedicinePhase 3
47